首页 Paratek生物制药(usPRTK)-基本信息

Paratek生物制药(usPRTK)-基本信息

日报更新时间:

周报更新时间:01-23 11:54

行情信息

今开价:

最高价:

成交量:

昨收价:

最低价:

最新价:

行情图标
概要信息

中文名称:Paratek生物制药


英文名称:Paratek Pharmaceuticals


简介:Paratek Pharmaceuticals, Inc.于2001年以Novacea之称成立,位于特拉华州,是一家专门的制药公司,专注于研发和销售解决在神经病领域有重要治疗需要的专有权产品


电话:1-617-8076600


最新量化综合结论
百科信息
  • 相关网站
  • 百科
  • 员工交易记录
  • 持股信息
  • 领导人信息

Paratek Pharmaceuticals是一家生物制药公司,为医院内外的患者开发难以治疗的疾病的变革性解决方案。专注于针对传染病和其他难以治疗的疾病的药物。Paratek Pharmaceuticals, Inc.主要候选产品omadacycline,一种静脉和口服抗生素,可用作急性细菌性皮肤和皮肤结构感染的单一疗法抗生素,社区获得性细菌性肺炎,尿路感染和其他社区获得性细菌感染;和Sarecycline,一种四环素衍生的化合物,设计用于治疗痤疮和红斑痤疮。Paratek Pharmaceuticals公司与Zai Lab (Shanghai) Co., Ltd.和Allergan plc签订了许可和合作协议;与塔夫斯大学(Tufts University)签订许可协议,开发和商业化用于治疗或预防细菌或微生物疾病或医疗条件的产品;与美国陆军传染病医学研究所(U.S. Army Medical Research Institute of Infectious Diseases)合作研发协议,研究针对致病传染病的致病因子的omadacycline。

交易日期 交易人 职位 类型 交易份额 价格
2017-07-18 Bigham (Michael F) Chief Executive Officer Buy 23255 4.30
2017-07-18 Loh (Evan) President Buy 39478 4.30
2017-07-04 Bigham (Michael F) Chief Executive Officer Sell 5075 23.58
2017-07-04 Pagan (Douglas W) Chief Financial Officer Sell 4139 23.58
2017-07-04 Woodrow (Adam) Officer Sell 3800 23.58
2017-07-04 Haskel William M General Counsel Sell 2461 23.58
2017-07-04 Loh (Evan) President Sell 4351 23.58
2017-07-02 Haskel William M General Counsel Buy 7000 --
2017-07-02 Loh (Evan) President Buy 13000 --
2017-07-02 Woodrow (Adam) Officer Buy 9500 --
2017-07-02 Bigham (Michael F) Chief Executive Officer Buy 14500 --
2017-07-02 Pagan (Douglas W) Chief Financial Officer Buy 9000 --
2017-06-18 Pagan (Douglas W) Chief Financial Officer Sell 4595 25.00
2017-02-05 Loh (Evan) President Sell 16 15.08
2017-02-05 Loh (Evan) President Sell 668 15.15
2017-02-05 Pagan (Douglas W) Chief Financial Officer Sell 1186 15.05
2017-02-05 Pagan (Douglas W) Chief Financial Officer Sell 25 15.09
2017-02-05 Pagan (Douglas W) Chief Financial Officer Sell 17 15.08
2017-02-05 Pagan (Douglas W) Chief Financial Officer Sell 1428 15.10
2017-02-05 Pagan (Douglas W) Chief Financial Officer Sell 732 15.15
2017-02-05 Pagan (Douglas W) Chief Financial Officer Sell 17 15.20
2017-02-05 Loh (Evan) President Sell 1302 15.10
2017-02-05 Loh (Evan) President Sell 1082 15.05
2017-02-05 Loh (Evan) President Sell 22 15.09
2017-02-05 Bigham (Michael F) Chief Executive Officer Sell 32 15.08
2017-02-05 Bigham (Michael F) Chief Executive Officer Sell 2104 15.10
2017-02-05 Bigham (Michael F) Chief Executive Officer Sell 30 15.20
2017-02-05 Bigham (Michael F) Chief Executive Officer Sell 1082 15.15
2017-02-05 Bigham (Michael F) Chief Executive Officer Sell 1752 15.05
2017-02-05 Loh (Evan) President Sell 16 15.20
第 页, 共 2 页 首页 上页 下页 末页

机构持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
Fortress Investment Group LLC 433804 1.34% -- -- 2019-03-31
Vanguard Group Inc 1101570 3.40% 485256 78.74% 2019-03-31
Fort Hoosac Management, LLC 1106422 3.41% -5514 -0.50% 2019-03-31
BlackRock Fund Advisors 1379430 4.26% -45 -- 2019-07-31
Armistice Capital, LLC 2124000 6.55% 156000 7.93% 2019-03-31
Baupost Group LLC 2394498 7.39% -- -- 2019-03-31
Highland Capital Management LP 2416993 7.46% 25000 1.05% 2019-03-31
BlackRock Inc 2607486 8.04% -68946 -2.58% 2019-03-31
Omega Fund Management LLC 5200820 16.04% 2600410 100.00% 2019-03-31
Abingworth LLP 1041131 3.21% -- -- 2019-03-31
Vanguard Investments Australia Ltd 961825 2.97% -20232 -2.06% 2019-07-31
Water Island Capital LLC 733296 2.26% 414778 130.22% 2019-03-31
Rock Springs Capital Management LP 450000 1.39% -- -- 2019-03-31
General American Investors Company Inc 464985 1.43% -- -- 2019-03-31
CAM Group Holding A/S 470150 1.45% -- -- 2019-03-31
Carnegie Asset Management Fondsm 470150 1.45% -- -- 2019-03-31
State Street Corporation 583443 1.80% 6451 1.12% 2019-03-31
Northern Trust Investments Inc 635862 1.96% 15654 2.52% 2019-07-31
Roumell Asset Management, LLC 657696 2.03% 207290 46.02% 2019-03-31
HBM Partners Cayman Ltd 698618 2.16% -8830 -1.25% 2019-07-31
Highbridge Capital Management, LLC 2201258 6.79% 2201258 -- 2018-04-23
BlackRock Asset Management Canada Ltd 677650 2.09% -445 -0.07% 2019-05-31
Geode Capital Management, LLC 617546 1.91% 315584 104.51% 2018-12-31
C WorldWide Asset Management Fondsm 470150 1.45% -9107 -1.90% 2019-04-30
Northern Trust Corp 412916 1.27% -19174 -4.44% 2018-12-31
Northern Trust Investments N A 432090 1.34% 23244 5.69% 2018-09-30
Fidelity SelectCo, LLC 784807 2.44% -125000 -13.74% 2018-11-30
BlackRock Institutional Trust Company NA 956411 2.98% 288612 43.22% 2018-06-30
Man Group PLC 475381 1.48% -71442 -13.06% 2018-06-30
Alyeska Investment Group, L.P. 483437 1.50% -943624 -66.12% 2018-06-30
Deutsche Bank AG 553728 1.72% 74528 15.55% 2018-06-30
Renaissance Technologies Corp 539949 1.68% -30900 -5.41% 2018-06-30
Fidelity Management and Research Company 1242751 3.87% 76459 6.56% 2018-03-31
FMR Inc 1242751 3.87% 76459 6.56% 2018-03-31
Sectoral Asset Management Inc 430843 1.54% -86357 -16.70% 2017-09-30
State Street Corp 517943 1.63% -109128 -17.40% 2018-06-30
Royce & Associates, LLC 389669 1.24% 29400 8.16% 2018-03-31
General American Investors Company, Inc. 308864 0.98% -- -- 2018-03-31
CommonWealth PPS 355740 1.12% -572408 -61.67% 2018-06-30
Brown Brothers Harriman & Co 287902 0.92% -- -- 2018-03-31
Hbm Bioventures Cayman Ltd 1200000 4.94% -150000 -11.11% 2017-03-10
NORGES BANK 526977 1.89% 430477 446.09% 2017-12-31
Numeric Investors LLC 374920 1.34% 141800 60.83% 2017-12-31
Pictet Asset Management SA 788246 2.82% 126251 19.07% 2017-12-31
Empyrean Capital Partners, LP 669000 2.39% -- -- 2017-12-31
Broadfin Capital, LLC 406207 1.46% 129187 46.63% 2017-09-30
Franklin Advisers Inc 360000 1.29% -148066 -29.14% 2017-09-30
Millennium Management LLC 334353 1.20% 313144 1476.47% 2017-09-30
Tekla Capital Management LLC 762581 3.37% -- -- 2016-09-30
Aisling Capital LLC 482680 2.13% -- -- 2016-09-30
Granahan Investment Management Inc.. 423230 1.87% 72030 20.51% 2016-09-30
Sabby Management LLC 175000 0.77% -130964 -42.80% 2016-09-30
Robeco Investment Management, Inc. 136227 0.60% 136227 -- 2016-12-31
Entities affiliated with Omega Funds 1505629 3.00% 44220324 0.10% 1999-11-30
Baupost Group Securities, L.L.C. 1735218 3.00% 50963353 0.10% 1999-11-30
HBM Healthcare Investments (Cayman) Ltd. 1765058 3.00% 51839753 0.10% 1999-11-30
共同基金持股
持有者 持有份额 持股比例 份额变化 变化率 报告日期
State Street Russell Small/Mid Cap 121494 0.37% -- -- 2019-06-30
iShares Russell 2000 Growth ETF 303108 0.94% -- -- 2019-07-30
iShares Nasdaq Biotechnology ETF 314777 0.97% -936 -0.30% 2019-07-30
Vanguard Extended Market Index Fund 421595 1.30% -- -- 2019-06-30
General American Investors 464985 1.43% -- -- 2019-03-31
Roumell Opportunistic Value Fund 589825 1.82% -- -- 2019-06-30
iShares Russell 2000 ETF 659497 2.03% 1287 0.20% 2019-07-30
HBM Healthcare Investments AG 698618 2.16% -8830 -1.25% 2019-06-30
Vanguard Total Stock Market Index Fund 961825 2.97% -- -- 2019-06-30
Bruce Fund 266552 0.82% 266552 -- 2019-06-30
JPMorgan US Small Company Fund 235600 0.73% -13800 -5.53% 2019-06-30
Fidelity 126875 0.39% 14928 13.33% 2019-04-30
NT R2000 Index Fund - NL 128922 0.40% 5187 4.19% 2019-06-30
State Street Russell Small Cap 136202 0.42% -- -- 2019-06-30
Litman Gregory Masters Alt Strats Fund 137303 0.42% -- -- 2019-06-30
NT R2000 Growth Index Fund - Non-Lending 141224 0.44% -- -- 2019-06-30
DFA US Small Cap Portfolio 147618 0.46% -- -- 2019-05-31
APO Medical Opportunities 147991 0.46% -- -- 2019-06-30
MEDICAL BioHealth 227383 0.70% -- -- 2019-04-30
Gim Small Cap Advantage 115900 0.36% -1600 -1.36% 2018-12-31
Royce Low-Priced Stock Fund 126100 0.39% -- -- 2019-03-31
iShares US Small Cap ETF (CAD-Hedged) 629428 1.94% -1053 -0.17% 2019-05-30
C WorldWide Medical 470150 1.45% -- -- 2019-03-31
JNL Multi-Manager Small Cap Growth Fund 115900 0.36% -1600 -1.36% 2018-12-31
SPDR 157821 0.49% -- -- 2018-06-15
Royce Capital Fund Micro-Cap Portfolio 94600 0.29% -13100 -12.16% 2018-12-31
Boston Partners Long/Short Equity Fund 98587 0.31% -18400 -15.73% 2018-06-30
TETON Westwood Mighty Mites Fund 108000 0.33% 84000 350.00% 2018-12-31
Royce Micro Cap Series Fund 91600 0.28% -11400 -11.07% 2018-12-31
Schwab US Small-Cap ETF 81366 0.25% -- -- 2019-01-31
FCP MEDICAL BioHealth-Trends 227383 0.70% 37725 19.89% 2018-10-31
International Biotechnology 103500 0.32% 103500 -- 2018-03-31
OMI IM GBP AXA Framlington Biotech 189721 0.59% 189721 -- 2018-10-31
C WorldWide Medical Small & Mid Cap 157742 0.49% -- -- 2018-09-30
Fidelity Advisor 197660 0.61% -32000 -13.93% 2018-05-31
Franklin Biotechnology Discovery Fund 131500 0.41% -54163 -29.17% 2017-09-30
Invesco Health Care Fund 138873 0.43% -90303 -39.40% 2017-09-30
Nomura World Genome Tech Open Mother 308200 0.96% 308200 -- 2017-11-20
Pictet-Biotech 430843 1.34% -86357 -16.70% 2017-09-30
Litman Gregory Masters Alt Strats Instl 155203 0.49% 15136 10.81% 2018-06-30
Northern Trust Russell 2000 Index Fund - DC - Non-Lending 76504 0.24% 109 0.14% 2018-07-31
Vanguard Total Stock Mkt Idx 805979 2.54% 44800 5.89% 2018-07-31
Vanguard Extended Market Idx Inv 379624 1.20% -- -- 2018-07-31
iShares Nasdaq Biotechnology 360601 1.07% -687 -0.19% 2018-09-12
iShares Russell 2000 Growth 302062 0.90% -291 -0.10% 2018-09-12
JPMorgan US Small Company Instl 278800 0.88% 5500 2.01% 2018-07-31
Roumell Opportunistic Value A 200644 0.63% -- -- 2018-08-31
Rainier Small/Mid Cap Equity Original 78920 0.28% -6870 -8.01% 2017-09-30
State Street Russell Small/Mid Cap Idx Fd Cl I 71558 0.26% 16933 31.00% 2017-06-30
Royce Low Priced Stock Svc 127000 0.40% 23100 22.23% 2018-06-30
Royce Capital Micro-Cap Inv 78600 0.25% 16800 27.18% 2018-06-30
iShares Micro-Cap 83542 0.25% -- -- 2018-09-12
Royce Micro-Cap Invmt 79200 0.25% 14600 22.60% 2018-06-30
Royce Smaller-Companies Growth Svc 87700 0.28% -36300 -29.27% 2018-06-30
Boston Partners Long/Short Equity Instl 98587 0.31% -18400 -15.73% 2018-06-30
JNL Multi-Manager Small Cap Growth B 110500 0.35% 110500 -- 2018-06-30
Fidelity Spartan 124492 0.39% -- -- 2018-07-31
Ohio National Bryton Growth 70422 0.22% -- -- 2018-03-31
CREF Stock R1 98753 0.31% -21900 -18.15% 2018-04-30
Russell US Small Cap Equity I 70442 0.22% -- -- 2018-02-28
Guggenheim Raymond James SB-1 Equity ETF 89226 0.31% -- -- 2018-03-08
Dreyfus Select Managers Small Cap Val A 67945 0.24% -- -- 2017-12-31
Invesco Global Health Care A 138873 0.50% -90303 -39.40% 2017-09-30
Franklin Biotechnology Discovery A 131500 0.47% -54163 -29.17% 2017-09-30
Tekla Healthcare Investors 483700 2.14% -- -- 2016-09-30
Tekla Life Sciences Investors 207300 0.92% -- -- 2016-09-30
Vanguard VIF Small Co Gr 116870 0.52% 40800 53.63% 2016-09-30
Turner Medical Sciences Long/Short C 60710 0.27% -- -- 2016-12-31
The Vanguard Russell 2000 Growth Index 29985 0.13% 1100 3.81% 2016-12-31
BlackRock Extended Equity Market K 28344 0.13% 1047 3.84% 2016-12-31
Fidelity Advisor® Biotechnology Fund 683303 3.90% -- -- 2015-09-30
Prudential Jennison Health Sciences 203555 1.20% -- -- 2015-09-30
iShares Russell 2000 (AU) 197187 1.20% -246 -0.10% 2015-11-19
Vanguard VIF Small Comp Gr 183060 1.00% 155800 571.50% 2015-09-30
Vanguard US Discoveries Fund 100655 0.60% -- -- 2015-07-31
Turner Medical Sciences Long/Short 52720 0.30% 52720 -- 2015-09-30
BNY Mellon Small Cap Multi-Strategy Fund 44009 0.20% -- -- 2015-09-30
CREF Stock Account 39584 0.20% -4930 -11.10% 2015-09-30
Fidelity® Select Biotechnology Portfolio 1727718 9.80% -- -- 2015-09-30

Jeanne Y. Jew Jeanne Y. Jew is Senior Vice President-Business Development for Paratek Pharmaceuticals, Inc. Ms. Jew previously was Vice President-Business Development for Deltagen, Inc., Principal at Scios, Inc., VP-Corporate & Commercial Development at Onyx Pharmaceuticals, Inc., Vice President-Business Development for Coulter Pharmaceuticals, Inc., Senior Vice President-Business Development for Humanigen, Inc. and Principal at Genentech, Inc. Jeanne Y. Jew received an undergraduate degree from Wesleyan University and an MBA from Cornell University.
Michael F. Bigham Mr. Michael F. Bigham is Chairman & Chief Executive Officer at Paratek Pharmaceuticals, Inc. and Executive Partner at Abingworth Management Ltd. He is on the Board of Directors at Adamas Pharmaceuticals, Inc. and Inmediata Health Group. Mr. Bigham was previously employed as Chairman & Chief Executive Officer by Paratek Pharmaceuticals, Inc. /Old/, an Independent Director by Supernus Pharmaceuticals, Inc., Executive Partner by Abingworth LLP, Vice Chairman by Corixa Corp., President & Chief Executive Officer by Coulter Pharmaceuticals, Inc., Chief Financial Officer & Executive VP-Operations by Gilead Sciences, Inc., Co-Head-Healthcare Investment Banking by Hambrecht & Quist Group, Inc., and Chairman by Magellan Diagnostics, Inc. He also served on the board at Avedro, Inc., Avila Therapeutics, Inc., Dynogen Pharmaceuticals, Inc., Hydra Biosciences, Inc., Portola Pharmaceuticals, Inc., PrimeraDx, Inc., Valeritas, Inc. and Xenogen Corp. Mr. Bigham received his undergraduate degree from the University of Virginia and an MBA from Stanford University.
Thomas John Dietz Thomas John Dietz is a businessperson who has been at the head of 5 different companies. Currently, he occupies the position of Chairman & Chief Executive Officer at Waypoint Holdings LLC, Independent Chairman for Eiger BioPharmaceuticals, Inc. and Chairman for Galleon Pharmaceuticals, Inc. He is also Managing Member at Codpiece Properties LLC and Managing Member at Codfish Investments LLC and on the board of 6 other companies. In the past Dr. Dietz was Co-Chief Executive Officer of Pacific Growth Equities, Inc., Head-Investment Banking at Wedbush Securities, Inc., Research Faculty Member at VA Medical Center (District of Columbia), Trustee-West Bay Region at Sutter Health and Research Faculty Member at The University of California, San Francisco. He received a doctorate from Washington University in St. Louis and an undergraduate degree from State University of New York at Albany.
Jeffrey L. Stein Jeffrey L. Stein founded Quorex Pharmaceuticals, Inc. and Antibiotics Working Group. Currently, he occupies the position of President, Chief Executive Officer & Director at Cidara Therapeutics, Inc. Dr. Stein is also on the board of Prevacept Infection Control, Inc., Paratek Pharmaceuticals, Inc. and IDEAYA Biosciences, Inc. Jeffrey L. Stein previously occupied the position of Chairman & President of Antibiotics Working Group, Director, Chief Scientific Officer & Executive VP at Quorex Pharmaceuticals, Inc., Venture Partner at Sofinnova Ventures, Inc., President, Chief Executive Officer & Director at Trius Therapeutics, Inc., Principal Scientist at Diversa Corp., Chairman for Antimicrobials Working Group, Principal Scientist at The Agouron Institute and Director-Venture Development at the University of California San Diego. Dr. Stein received a doctorate from the University of California San Diego, an undergraduate degree and a graduate degree from The California State University and a doctorate from California Institute of Technology.
Sarah Higgins Sarah Higgins holds the position of VP, Chief Financial & Accounting Officer at Paratek Pharmaceuticals, Inc. In her past career she was Finance Director & Controller at Hurley of America, Inc. She received an undergraduate degree from Fairfield University.
Rolf K. Hoffmann Presently, Rolf K. Hoffmann occupies the position of Chairman-Supervisory Board at Biotest AG and Chairman for Biotest Pharmaceuticals Corp. He is also on the board of 8 other companies. In the past he was General Manager-Germany at Eli Lilly & Co. and Chief Executive Officer-Global Marketing at Lilly Deutschland GmbH (a subsidiary of Eli Lilly & Co.) and Senior Vice President-US Commercial Operations at Amgen, Inc. and Senior VP-International Commercial Operations at Amgen (Europe) GmbH (a subsidiary of Amgen, Inc.). Rolf K. Hoffmann received a graduate degree from Universit�0�1¤t zu K�0�1�0�9ln, a graduate degree from Deutsche Sporthochschule K�0�1�0�9ln and an MBA from the University of North Carolina at Chapel Hill.
Jeanne Y. Jew Jeanne Y. Jew is Senior Vice President-Business Development of Paratek Pharmaceuticals, Inc. In the past Ms. Jew held the position of Vice President-Business Development at Deltagen, Inc., Principal at Scios, Inc., VP-Corporate & Commercial Development at Onyx Pharmaceuticals, Inc., Vice President-Business Development at Coulter Pharmaceuticals, Inc., Senior Vice President-Business Development of Humanigen, Inc. and Principal at Genentech, Inc. She received an undergraduate degree from Wesleyan University and an MBA from Cornell University.
Jeffrey L. Stein Jeffrey L. Stein founded Quorex Pharmaceuticals, Inc. and Antibiotics Working Group. Currently, he occupies the position of President, Chief Executive Officer & Director at Cidara Therapeutics, Inc. Dr. Stein is also on the board of Prevacept Infection Control, Inc., Paratek Pharmaceuticals, Inc. and IDEAYA Biosciences, Inc. Jeffrey L. Stein previously occupied the position of Chairman & President of Antibiotics Working Group, Director, Chief Scientific Officer & Executive VP at Quorex Pharmaceuticals, Inc., Venture Partner at Sofinnova Ventures, Inc., President, Chief Executive Officer & Director at Trius Therapeutics, Inc., Principal Scientist at Diversa Corp., Chairman for Antimicrobials Working Group, Principal Scientist at The Agouron Institute and Director-Venture Development at the University of California San Diego. Dr. Stein received a doctorate from the University of California San Diego, an undergraduate degree and a graduate degree from The California State University and a doctorate from California Institute of Technology.
Thomas John Dietz Thomas John Dietz is a businessperson who has been at the head of 5 different companies. Currently, he occupies the position of Chairman & Chief Executive Officer at Waypoint Holdings LLC, Independent Chairman for Eiger BioPharmaceuticals, Inc. and Chairman for Galleon Pharmaceuticals, Inc. He is also Managing Member at Codpiece Properties LLC and Managing Member at Codfish Investments LLC and on the board of 6 other companies. In the past Dr. Dietz was Co-Chief Executive Officer of Pacific Growth Equities, Inc., Head-Investment Banking at Wedbush Securities, Inc., Research Faculty Member at VA Medical Center (District of Columbia), Trustee-West Bay Region at Sutter Health and Research Faculty Member at The University of California, San Francisco. He received a doctorate from Washington University in St. Louis and an undergraduate degree from State University of New York at Albany.
Timothy R. Franson Prior to joining Cardinal Equity Partner in 2008, Dr. Franson worked at Eli Lilly & Co. as Vice President of Global Regulatory Affairs. Previously, he was Vice President-US Clinical Research and Regulatory Affairs of Lilly Research Laboratories. Currently, Dr. Franson is a Fellow of the American College of Physicians and the Infectious Diseases Society of America and a Member of the American Federation for Clinical Research and the American Society for Microbiology. He is Chairman of the Clinical Steering Committee and a Member of the Regulatory Affairs Coordinating Committee of the Pharmaceutical Research and Manufacturers' Association (PhRMA). He is a Member of the Editorial Advisory Board for FDA Advertising & Promotional Manual, a Trustee for Xavier University of Louisiana and a Director Villages of Indiana and the Indiana State Museum Foundation. Dr. Frason received a BS degree in Pharmacy from Drake University in 1974 and an MD from the University of Illinois College of Medicine in 1978.
Benjamin J. Strain Benjamin J. Strain holds the position of Head-Investor Relations & Communications at Paratek Pharmaceuticals, Inc. In his past career Mr. Strain was Senior Manager-Investor Relations at Biogen, Inc. and Associate Portfolio Manager at The Boston Company Asset Management LLC.
Robert Samuel Radie Mr. Robert S. Radie is an Independent Director at Veloxis Pharmaceuticals A/S, an Independent Director at Paratek Pharmaceuticals, Inc., a President, CEO, CFO & Director at Egalet Corp. and a Chief Executive Officer at Egalet US, Inc. He is on the Board of Directors at Veloxis Pharmaceuticals A/S, Life Sciences Pennsylvania, Paratek Pharmaceuticals, Inc., Egalet Ltd., Egalet Corp. and Horse Power For Life. Mr. Radie was previously employed as a President & Chief Executive Officer by Topaz Pharmaceuticals, Inc., a President & Chief Executive Officer by TransMolecular, Inc., a Chief Business Officer & Executive Vice President by Prestwick Pharmaceuticals, Inc., a Principal by Eli Lilly & Co., a Chief Business Officer by Morphotek, Inc., and a Senior VP-Strategic Projects & Planning by Vicuron Pharmaceuticals LLC. He also served on the board at Affinium Pharmaceuticals Ltd. He received his undergraduate degree from Boston College.
Kristine Peterson Kristine Peterson is on the board of ImmunoGen, Inc. and 7 other companies. Ms. Peterson previously held the position of Chief Executive Officer for Valeritas Holdings, Inc. and Chief Executive Officer & Director at Valeritas, Inc. (a subsidiary of Valeritas Holdings, Inc.), Group Chairman-Biotech Groups at Johnson & Johnson, Principal at Bristol-Myers Squibb Co., President at Biovail Pharmaceuticals LLC and Senior Vice President-Commercial Operations at Biovail Corp. Ms. Peterson received an MBA and an undergraduate degree from the University of Illinois.
William M. Haskel William M. Haskel holds the position of Secretary, General Counsel & Senior Vice President at Paratek Pharmaceuticals, Inc. Mr. Haskel is also Member of New Jersey State Bar Association and Member of New York State Bar Association. In his past career Mr. Haskel was Associate at Olwine, Connelly, Chase, O'Donnell & Weyher, Secretary, Chief Compliance Officer & Senior VP at Cambrex Corp., Associate at Hale & Dorr LLP and Vice President & Associate General Counsel at Wyeth Corp. Mr. Haskel received a graduate degree from George Washington University Law School and an undergraduate degree from Franklin & Marshall College.
Douglas W. Pag�0�1�0�3n Douglas W. Pag�0�1�0�3n occupies the position of Chief Financial & Accounting Officer for Paratek Pharmaceuticals, Inc. He is also on the board of ZIOPHARM Oncology, Inc. In his past career he was Finance Director of Biogen, Inc., Vice President-Finance at Acceleron Pharma, Inc., Senior Engineer at Johnson & Johnson, Manager-International Treasury at Bristol-Myers Squibb Co. and Associate for JPMorgan Investment Bank. He received an undergraduate degree from Princeton University and an MBA from Columbia Business School.
Evan Loh Currently, Evan Loh occupies the position of Chief Executive Officer & Director at Paratek Pharmaceuticals, Inc. He is also on the board of Eiger BioPharmaceuticals, Inc. and Chairman of Antimicrobials Working Group. In his past career he held the position of Senior VP-Worldwide Research & Development at Pfizer Inc. Vice President-Clinical Research & Development at Wyeth Corp. and Vice President-Multiple Therapeutic Areas at Wyeth Pharmaceuticals LLC (both are subsidiaries of Pfizer Inc.), President, Director & Chief Medical Officer at Paratek Pharmaceuticals, Inc., Member of Harvard Medical School and Member of Perelman School of Medicine. He received a doctorate from Harvard Medical School and an undergraduate degree from Harvard College.
Adam Woodrow Adam Woodrow is President & Chief Commercial Officer at Paratek Pharmaceuticals, Inc. In his past career he occupied the position of Head-Global Strategic Marketing at Pfizer Inc. and Vice President & Global Business Manager at Wyeth Pharmaceuticals LLC (a subsidiary of Pfizer Inc.). Mr. Woodrow received an undergraduate degree from The University of Wales.
Adam Woodrow Adam Woodrow is President & Chief Commercial Officer at Paratek Pharmaceuticals, Inc. In his past career he occupied the position of Head-Global Strategic Marketing at Pfizer Inc. and Vice President & Global Business Manager at Wyeth Pharmaceuticals LLC (a subsidiary of Pfizer Inc.). Mr. Woodrow received an undergraduate degree from The University of Wales.
Susan M. Perkins Susan M. Perkins is Vice President-Intellectual Property at Paratek Pharmaceuticals, Inc. Ms. Perkins previously was Head-Intellectual Property at Aileron Therapeutics, Inc. Ms. Perkins received a graduate degree from George Washington University, an undergraduate degree from the University of North Carolina at Chapel Hill and an undergraduate degree from the University of Massachusetts.
Randy Brenner Presently, Randy Brenner is Chief Development & Regulatory Officer at Paratek Pharmaceuticals, Inc. In his past career he held the position of Vice President-Established Products Business Units at Pfizer Inc. and Head-Regulatory Affairs at Shire Plc.
Raj Padmanabhan Raj Padmanabhan is Vice President-Information Technology at Paratek Pharmaceuticals, Inc. In his past career he held the position of Associate Director-Business & Integration Service at Biogen-Idec Pharmaceuticals, Inc. and Senior Director-IT Architecture & Processes at Cubist Pharmaceuticals LLC. He received an undergraduate degree from the University of Madras and an MBA from Babson College.
Raj Padmanabhan Raj Padmanabhan is Vice President-Information Technology at Paratek Pharmaceuticals, Inc. In his past career he held the position of Associate Director-Business & Integration Service at Biogen-Idec Pharmaceuticals, Inc. and Senior Director-IT Architecture & Processes at Cubist Pharmaceuticals LLC. He received an undergraduate degree from the University of Madras and an MBA from Babson College.
Paul McGovern Currently, Paul McGovern occupies the position of Vice President-Clinical & Medical Affairs at Paratek Pharmaceuticals, Inc. Dr. McGovern received an undergraduate degree from the University of Notre Dame and a doctorate from Northwestern University.
Christine R. Coyne Currently, Christine R. Coyne is Vice President-Marketing of Paratek Pharmaceuticals, Inc.
RoN Jackson RoN Jackson holds the position of Vice President-National Sales at Paratek Pharmaceuticals, Inc. He received an undergraduate degree from Baylor University.
Jason Burdette Jason Burdette is Vice President-Technical Operations at Paratek Pharmaceuticals, Inc. Mr. Burdette previously was Vice President-Supply Chain at Eagle Pharmaceuticals, Inc. and VP-Geographic Expansion Strategy & Planning at Shire Pharmaceuticals, Inc.

量化对比

全部评论 0

  • 暂无评论

阿布量化公众号二维码 abu_quant 扫一扫关注阿布量化

热门推荐